Episode
Ep. 318 Exploring Neuromodulation: Sacral vs Tibial Approaches with Dr. Ken Peters and Dr. Tracey Wilson
- Podcast
- BackTable Urology
- Published
- Jul 21, 2026
- Duration seconds
- 3600
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/BTL4362931208.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/backtable-urology-3724776/episodes/ep-318-exploring-neuromodulation-sacral-vs-tibial-approaches-with-dr-ken-peters-and-dr-tracey-wilson/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/backtable-urology-3724776/ep-318-exploring-neuromodulation-sacral-vs-tibial-approaches-with-dr-ken-peters-and-dr-tracey-wilson.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
More neuromodulation options mean more opportunities to personalize care. In this episode, Dr. Ken Peters and Dr. Tracey Wilson join Dr. Jannah Thompson to discuss the latest implantable tibial nerve stimulation and sacral neuromodulation technologies for OAB and UUI. They compare available devices, share practical insights on patient selection, and explore how shared decision making, advanced practice providers, and equitable access influence treatment adoption. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast was developed in collaboration with Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) https://sufuorg.com/home.aspx --- Timestamps 00:00 - Introduction07:59 - Overview of Nerve Stimulation Therapies13:22 - Case #122:00 - Case #228:23 - Nuspera 34:21 - APPs in Practice39:21 - Reimbursement Roadblocks47:03 - Multimodal Therapy49:51 - Case #356:06 - Final Advice --- Resources Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trialhttps://www.auajournals.org/doi/10.1016/j.juro.2009.12.036 Neuspera Medical Announces 12-Month Pivotal Trial Results for the Company’s Integrated Sacral Neuromodulation System for Urinary Urge Incontinencehttps://neuspera.com/neuspera-medical-announces-12-month-pivotal-trial-results-for-the-companys-integrated-sacral-neuromodulation-system-for-urinary-urge-incontinence/ Racial and Socioeconomic Factors Influence Utilization of Advanced Therapies in Commercially Insured OAB Patients: An Analysis of Over 800,000 OAB Patientshttps://www.sciencedirect.com/science/article/pii/S0090429520305574?via%3Dihub --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and uro…